vorinostat has been researched along with Minimal Disease, Residual in 2 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ellingson, BM | 1 |
| Abrey, LE | 1 |
| Nelson, SJ | 1 |
| Kaufmann, TJ | 1 |
| Garcia, J | 1 |
| Chinot, O | 1 |
| Saran, F | 1 |
| Nishikawa, R | 1 |
| Henriksson, R | 1 |
| Mason, WP | 1 |
| Wick, W | 1 |
| Butowski, N | 1 |
| Ligon, KL | 1 |
| Gerstner, ER | 1 |
| Colman, H | 1 |
| de Groot, J | 1 |
| Chang, S | 1 |
| Mellinghoff, I | 1 |
| Young, RJ | 1 |
| Alexander, BM | 1 |
| Colen, R | 1 |
| Taylor, JW | 1 |
| Arrillaga-Romany, I | 1 |
| Mehta, A | 1 |
| Huang, RY | 1 |
| Pope, WB | 1 |
| Reardon, D | 1 |
| Batchelor, T | 1 |
| Prados, M | 1 |
| Galanis, E | 1 |
| Wen, PY | 1 |
| Cloughesy, TF | 1 |
| Mahlknecht, U | 1 |
| Schönbein, C | 1 |
1 trial available for vorinostat and Minimal Disease, Residual
| Article | Year |
|---|---|
Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Contrast Media; Female; Follow-Up | 2018 |
1 other study available for vorinostat and Minimal Disease, Residual
| Article | Year |
|---|---|
Histone deacetylase inhibitor treatment downregulates VLA-4 adhesion in hematopoietic stem cells and acute myeloid leukemia blast cells.
Topics: Acute Disease; Bone Marrow Cells; Cell Adhesion; Cell Line, Tumor; Cell Movement; Down-Regulation; D | 2008 |